Journal ArticleDOI
Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.
Graham R. Foster,Christophe Hézode,Jean-Pierre Bronowicki,Giampiero Carosi,Ola Weiland,Lieselotte Verlinden,Rolf van Heeswijk,Ben van Baelen,Gaston Picchio,Maria Beumont +9 more
TLDR
Telaprevir monotherapy for 2 weeks reduces levels of HCV RNA in patients with chronic HCV genotype 2 infections, but has limited activity in patientsWith chronic hepatitis C virus genotype 3, the incidence of adverse events was similar among groups.About:
This article is published in Gastroenterology.The article was published on 2011-09-01. It has received 179 citations till now. The article focuses on the topics: Telaprevir & Ribavirin.read more
Citations
More filters
Journal ArticleDOI
The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.
TL;DR: Geno- and phenotypic resistance testing as well as clinical data on the importance of RAVs for conventional triple therapies with sofosbuvir, simeprevir, and daclatasvir and available interferon-free DAA combinations are discussed.
Journal ArticleDOI
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
Michael P. Manns,Stanislas Pol,Ira M. Jacobson,Patrick Marcellin,Stuart C. Gordon,Cheng Yuan Peng,Ting-Tsung Chang,Gregory T. Everson,Jeong Heo,Guido Gerken,Boris Yoffe,William J. Towner,Marc Bourlière,Sophie Metivier,Chi-Jen Chu,William Sievert,Jean-Pierre Bronowicki,Dominique Thabut,Youn-Jae Lee,Jia-Horng Kao,Fiona McPhee,Justin Kopit,Patricia Mendez,Misti Linaberry,Eric Hughes,Stephanie Noviello +25 more
TL;DR: Daclatasvir plus asunaprevir provided high sustained virological response rates in treatment-naive, non-responder, and ineligible, intolerant, or ineligible and intolerant patients, and was well tolerated in patients with HCV genotype 1b infection.
Journal ArticleDOI
Antiviral strategies in hepatitis C virus infection.
Christoph Sarrazin,Christophe Hézode,Christophe Hézode,Stefan Zeuzem,Jean-Michel Pawlotsky,Jean-Michel Pawlotsky +5 more
TL;DR: The proof of concept that IFN-free regimens may lead to HCV eradication has recently been brought, however, new drugs may be associated with troublesome side effects and drugdrug interactions, and the ideal IFn-free DAA combination remains to be found.
Journal ArticleDOI
Direct-acting antivirals for chronic hepatitis C
Janus Christian Jakobsen,Emil Eik Nielsen,Joshua Feinberg,Kiran Kumar Katakam,Kristina Fobian,Goran Hauser,Goran Poropat,Snezana Djurisic,Karl Heinz Weiss,M. Bjelakovic,Goran Bjelakovic,Sarah Louise Klingenberg,Jianping Liu,Dimitrinka Nikolova,Ronald L. Koretz,Christian Gluud +15 more
TL;DR: The authors could not reliably determine the effect of DAAs on the market or under development on the primary outcome of hepatitis C-related morbidity or all-cause mortality, and the overall quality of the evidence was low.
References
More filters
Journal ArticleDOI
Diagnosis, management, and treatment of hepatitis C: An update
TL;DR: This document has been approved by the AASLD, the Infectious Diseases Society of America, and the American College of Gastroenterology.
Journal ArticleDOI
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
Stephanos J. Hadziyannis,Sette H,Timothy R. Morgan,Balan,Moisés Diago,Patrick Marcellin,G. Ramadori,Henry C. Bodenheimer,David I. Bernstein,Mario Rizzetto,Stefan Zeuzem,Paul J. Pockros,A. Lin,Andrew M. Ackrill +13 more
TL;DR: Treatment with peginterferon-alpha2a and ribavirin may be individualized by genotype, and in patients infected with HCV genotype 1, 48 weeks of treatment was statistically superior to 24 weeks and standard-dose ribvirin was statistically inferior to low-dose Ribavirin.
Journal ArticleDOI
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection
John G. McHutchison,Gregory T. Everson,Stuart C. Gordon,Ira M. Jacobson,Mark S. Sulkowski,Robert S. Kauffman,Lindsay McNair,John Alam,Andrew J. Muir +8 more
TL;DR: Treatment with a telaprevir-based regimen significantly improved sustained virologic response rates in patients with genotype 1 HCV, albeit with higher rates of discontinuation because of adverse events.
Journal ArticleDOI
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
Christophe Hézode,Nicole Forestier,Geoffrey Dusheiko,Peter Ferenci,Stanislas Pol,Tobias Goeser,Jean-Pierre Bronowicki,Marc Bourlière,Shahin Gharakhanian,Leif Bengtsson,Lindsay McNair,Shelley George,Tara L. Kieffer,Ann D. Kwong,Robert S. Kauffman,John Alam,Jean-Michel Pawlotsky,Stefan Zeuzem +17 more
TL;DR: In this phase 2 study of patients infected with HCV genotype 1 who had not been treated previously, one of the three telaprevir groups had a significantly higher rate of sustained virologic response than that with standard therapy.
Journal ArticleDOI
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Alessandra Mangia,Rosanna Santoro,Nicola Minerva,G.L. Ricci,Vito Carretta,Marcello Persico,Francesco Vinelli,Gaetano Scotto,D. Bacca,Mauro Annese,Mario R. Romano,Franco Zechini,Fernando Sogari,Fulvio Spirito,Angelo Andriulli +14 more
TL;DR: Treatment with peginterferon and ribavirin for 16 weeks in patients infected with HCV genotype 2 or 3 results in a lower overall sustained virologic response rate than treatment with the standard 24-week regimen.
Related Papers (5)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson,John G. McHutchison,Geoffrey Dusheiko,Adrian M. Di Bisceglie,K. Rajender Reddy,Natalie Bzowej,Patrick Marcellin,Andrew J. Muir,Peter Ferenci,Robert Flisiak,Jacob George,Mario Rizzetto,Daniel Shouval,Ricard Sola,R. Terg,Eric M. Yoshida,Nathalie Adda,Leif Bengtsson,Abdul J. Sankoh,Tara L. Kieffer,Shelley George,Robert S. Kauffman,Stefan Zeuzem,Vertex Phar +23 more